BPG is committed to discovery and dissemination of knowledge
Featured Articles
4/29/2021 4:10:06 AM | Browse: 33 | Download: 42
Publication Name World Journal of Gastroenterology
Manuscript ID 62770
Country/Territory Italy
2021-01-26 15:04
Peer-Review Started
2021-01-26 15:13
To Make the First Decision
Return for Revision
2021-02-27 17:34
2021-03-09 16:19
Second Decision
2021-04-09 08:48
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2021-04-14 05:02
Articles in Press
2021-04-14 05:02
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2021-04-27 01:28
Publish the Manuscript Online
2021-04-29 02:12
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Evidence Review
Article Title Pancreatic adenocarcinoma: Beyond first line, where are we?
Manuscript Source Invited Manuscript
All Author List Sara Cherri, Silvia Noventa and Alberto Zaniboni
Funding Agency and Grant Number
Corresponding Author Sara Cherri, MD, Medical Assistant, Department of Oncology, Fondazione Poliambulanza, Via Bissolati 57, Brescia 25124, Italy. sara.m.cherri@gmail.com
Key Words Pancreatic adenocarcinoma; Second-line; Chemotherapy; Targeted therapy; Immunotherapy
Core Tip The incidence of pancreatic ductal adenocarcinoma is increasing, with anticipation of a large impact on the population. Despite achieving a survival gain in first-line treatment in the last decade, to date, little has been achieved in second-line treatment. The molecular and genetic characteristics of this tumour represent a fundamental challenge for preclinical and clinical research. In this review, we illustrate current clinical practice in second-line treatment for advanced pancreatic adenocarcinoma and the research landscape of potential future prospects.
Publish Date 2021-04-29 02:12
Citation Cherri S, Noventa S, Zaniboni A. Pancreatic adenocarcinoma: Beyond first line, where are we? World J Gastroenterol 2021; 27(17): 1847-1863
URL https://www.wjgnet.com/1007-9327/full/v27/i17/1847.htm
DOI https://dx.doi.org/10.3748/wjg.v27.i17.1847
Full Article (PDF) WJG-27-1847.pdf
Full Article (Word) WJG-27-1847.docx
Manuscript File 62770_Auto_Edited_LM.docx
Answering Reviewers 62770-Answering reviewers.pdf
Audio Core Tip 62770-Audio core tip.m4a
Conflict-of-Interest Disclosure Form 62770-Conflict-of-interest statement.pdf
Copyright License Agreement 62770-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate 62770-Language certificate.pdf
Peer-review Report 62770-Peer-review(s).pdf
Scientific Misconduct Check 62770-Scientific misconduct check.pdf
Scientific Editor Work List 62770-Scientific editor work list.pdf